Loading cancer entity…
Loading cancer entity…
Clinical trials
296 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (43)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02860000 | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | completed | Phase 2 | 96 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05545150 | Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study | completed | Phase 2 | 113 | Northwestern UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT01750073 | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | completed | Phase 2 | 92 | University of NebraskaOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01730833 | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | completed | Phase 2 | 63 | City of Hope Medical CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02689427 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03947151 | Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer(DEGASTIM) | completed | Phase 2 | 8 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02530489 | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03212170 | FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer | completed | Phase 2 | 21 | University of Wisconsin, MadisonOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03345420 | Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer(NOVEMBER) | completed | Phase 2 | 102 | University of UtahOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03188393 | Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery | completed | Phase 2 | 105 | NRG OncologyOTHER | 2 | May 22, 2025 | clinicaltrials |
| NCT03219476 | Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | completed | Phase 2 | 37 | Medical College of WisconsinOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04294225 | Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer | completed | Phase 2 | 161 | Mayo ClinicOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03206203 | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | completed | Phase 2 | 106 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02456857 | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01622868 | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | completed | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 3 | Oct 17, 2023 | clinicaltrials |
| NCT03454529 | The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer | completed | Phase 2 | 24 | Michael SimonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT00921115 | Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | completed | Phase 2 | 42 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT02526498 | Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery(TRIUMPH-T) | completed | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT01417286 | Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer | completed | Phase 2 | 69 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT02448771 | A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer | completed | Phase 1 / Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02282345 | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer | completed | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT01849250 | Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Dec 28, 2021 | clinicaltrials |
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX)(GeparX) | completed | Phase 2 | 780 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT01964924 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT00513695 | Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | completed | Phase 2 | 68 | University of WashingtonOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT00003199 | Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT02077569 | AKT Inhibitor in Oestrogen Positive Breast Cancer(STAKT) | completed | Phase 2 | 48 | University of NottinghamOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT02199418 | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer(SHPD001) | completed | Phase 2 | 132 | RenJi HospitalOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT00635050 | Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin | completed | Phase 2 | 32 | University of Alabama at BirminghamOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00070252 | Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 4, 2015 | clinicaltrials |
| NCT02190227 | RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment | completed | Phase 2 | 30 | Jewish General HospitalOTHER | 1 | Feb 4, 2015 | clinicaltrials |
| NCT00049114 | Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00429182 | Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer | completed | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 10, 2013 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials